News | June 04, 2007

Men With Inflammatory Marker Have Three Times Higher Risk Of Heart Disease

June 5, 2007 — Men whose blood tests positive for the auto-antibody rheumatoid factor have a three times higher risk of heart disease, according to a study published online ahead of print in Heart.

This increased risk was similar to that found for the well-known risk factors of diabetes (2.5 times) and high blood pressure (4.4 times). However, rheumatoid factor was not found to increase the risk of heart disease in women.

The findings add more weight to the growing evidence that inflammation is implicated in atherosclerosis - a hardening of the arteries, when fats are deposited in the artery walls. It also raises the possibility that auto-immune processes and rheumatoid factor in particular may actually have a role in the disease process itself.

This build up of fatty deposits reduces blood supply to the heart (known as ischaemic heart disease) leading to angina and an increased risk of heart attack.

Rheumatoid factor is an auto-antibody present in up to 15% of adults and is strongly associated with rheumatoid arthritis. Chronic inflammatory diseases, such as rheumatoid arthritis, have been shown previously to increase the risk of ischaemic heart disease.

However, the prevalence of rheumatoid arthritis in men in the UK is only about 0.4 per cent, so rheumatoid factor therefore seems to be an independent risk factor in men. Rheumatoid factor can be measured by a simple blood test available in all hospitals.

The study involved 567 men and 589 women born between 1931 and 1937 who were assessed for a history of ischaemic heart disease, rheumatoid factor and traditional risk factors for heart disease. They were also assessed for other common auto-antibodies (antinuclear antibodies and anticardiolipin antibodies), but no link to increased risk of ischaemic heart disease was found.

Another inflammatory marker C-reactive protein has also been linked to the development of ischaemic heart disease in previous studies.

The autoantibody rheumatoid factor may be an independent risk factor for ischaemic heart disease in men.

For more information visit: www.heart.bmj.com

Related Content

Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing| May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing| May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing| April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing| April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
highly sensitive troponin testing
News | Cardiac Diagnostics| March 21, 2017
March 21, 2017 — A blood test for a protein called high-sensitivity troponin T, which is released into the bloodstrea
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing| March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing| January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...

The Xprecia Stride Coagulation Analyzer delivers fast, reliable prothrombin time/international normalized ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist. It is the latest INR testing system to enter the market in late 2016. Read the article “Siemens Receives FDA Clearance of Xprecia Stride Coagulation Analyzer.”
 

 

Feature | Point of Care Testing| December 30, 2016 | Ravi Chawat
Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology
Overlay Init